Michael L Hendrickson

US Patent:

20110263613, Oct 27, 2011

Filed:

Jan 11, 2011

Appl. No.:

13/004877

Inventors:

Michael L. Hendrickson - Madison WI, US
Jeffrey C. Ockuly - Madison WI, US
Trevor M. Twose - Fitchburg WI, US
Melinda L. Verdone - Waunakee WI, US
Brent D. Abraham - Verona WI, US
Richard R. Copp - Oregon WI, US
James G. Farnham - Madison WI, US
Seth A. Hanson - Madison WI, US

International Classification:

A61K 31/506
A61K 31/438
A61P 25/18
A61K 31/4245
A61P 25/04
A61P 25/28
C07D 413/04
A61K 31/454

US Classification:

514256, 546112, 514299, 546209, 514326, 548131, 514364, 544333

Abstract:

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

US Patent:

20120046273, Feb 23, 2012

Filed:

Mar 5, 2010

Appl. No.:

13/255096

Inventors:

Trevor M. Twose - Fitchburg WI, US
Brent D. Abraham - Verona WI, US
Richard R. Copp - Oregon WI, US
James G. Farnham - Madison WI, US
Seth A. Hanson - Madison WI, US
Michael L. Hendrickson - Madison WI, US
Jeffrey C. Ockuly - Madison WI, US
Melinda L. Verdone - Waunakee WI, US

Assignee:

MITHRIDION, INC. - MADISON WI

International Classification:

A61K 31/55
C07D 417/04
A61P 25/28
A61K 31/4439
A61K 31/4245
A61K 31/433
C07D 413/04
A61K 31/506

US Classification:

5142171, 544333, 548131, 5462694, 5462687, 540603, 514256, 514340, 514342, 548128, 514364, 514361

Abstract:

Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions.

US Patent:

20130274299, Oct 17, 2013

Filed:

Mar 8, 2013

Appl. No.:

13/791251

Inventors:

Richard R. Copp - Oregon WI, US
James G. Farnham - Madison WI, US
Seth A. Hanson - Madison WI, US
Michael L. Hendrickson - Madison WI, US
Jeffrey C. Ockuly - Madison WI, US
Trevor M. Twose - Fitchburg WI, US
Melinda L. Verdone - Waunakee WI, US

International Classification:

C07D 413/04

US Classification:

514364, 548131

Abstract:

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

US Patent:

20180099956, Apr 12, 2018

Filed:

Aug 18, 2017

Appl. No.:

15/680477

Inventors:

- Madison WI, US
Richard R. Copp - Oregon WI, US
James G. Farnham - Madison WI, US
Seth A. Hanson - Madison WI, US
Michael L. Hendrickson - Madison WI, US
Jeffrey C. Ockuly - Madison WI, US
Trevor M. Twose - Fitchburg WI, US
Melinda L. Verdone - Waunakee WI, US

International Classification:

C07D 413/04
C07D 403/04
C07D 417/04
C07B 59/00

Abstract:

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

US Patent:

20160340348, Nov 24, 2016

Filed:

Jul 29, 2016

Appl. No.:

15/224287

Inventors:

- Madison WI, US
Richard R. Copp - Oregon WI, US
James G. Farnham - Madison WI, US
Seth A. Hanson - Madison WI, US
Michael L. Hendrickson - Madison WI, US
Jeffrey C. Ockuly - Madison WI, US
Trevor M. Twose - Fitchburg WI, US
Melinda L. Verdone - Waunakee WI, US

International Classification:

C07D 413/04
C07B 59/00

Abstract:

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

US Patent:

20160199356, Jul 14, 2016

Filed:

Nov 2, 2015

Appl. No.:

14/930427

Inventors:

- Madison WI, US
Richard R. Copp - Oregon WI, US
James G. Farnham - Madison WI, US
Seth A. Hanson - Madison WI, US
Michael L. Hendrickson - Madison WI, US
Jeffrey C. Ockuly - Madison WI, US
Trevor M. Twose - Fitchburg WI, US
Melinda L. Verdone - Waunakee WI, US

International Classification:

A61K 31/4245

Abstract:

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.